HMGB1 and colitis: Recent studies indicated the roles of extracellular HMGB1 in inflammation-associated disease pathogenesis; the administration of neutralizing anti-HMGB1 antibodies or HMGB1 inhibitors significantly reduces inflammatory conditions in sepsis, arthritis, colitis, and ischemic reperfusion [4, 7–9].